TY - JOUR
T1 - Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension
AU - Hassoun, Paul M.
AU - Zamanian, Roham T.
AU - Damico, Rachel
AU - Lechtzin, Noah
AU - Khair, Rubina
AU - Kolb, Todd M.
AU - Tedford, Ryan J.
AU - Hulme, Olivia L.
AU - Housten, Traci
AU - Pisanello, Chiara
AU - Sato, Takahiro
AU - Pullins, Erica H.
AU - Corona-Villalobos, Celia P.
AU - Zimmerman, Stefan L.
AU - Gashouta, Mohamed A.
AU - Minai, Omar A.
AU - Torres, Fernando
AU - Girgis, Reda E.
AU - Chin, Kelly
AU - Mathai, Stephen C.
N1 - Publisher Copyright:
Copyright © 2015 by the American Thoracic Society.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Background: Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is a rare disease characterized by a very dismal response to therapy and poor survival. We assessed the effects of up-front combination PAH therapy in patients with SSc-PAH. Methods: In this prospective, multicenter, open-label trial, 24 treatment-naive patients with SSc-PAH received ambrisentan 10 mg and tadalafil 40 mg daily for 36 weeks. Functional, hemodynamic, and imaging (cardiac magnetic resonance imaging and echocardiography) assessments at baseline and 36 weeks included changes in right ventricular (RV) mass and pulmonary vascular resistance as co-primary endpoints and stroke volume/pulmonary pulse pressure ratio, tricuspid annular plane systolic excursion, 6-minute walk distance, and N-terminal pro-brain natriuretic peptide as secondary endpoints. Results: At 36 weeks, we found that treatment had resulted in significant reductions in median (interquartile range [IQR])RVmass (28.0 g [IQR, 20.6-32.9] vs. 32.5 g [IQR, 23.2-41.4]; P<0.05) and median pulmonary vascular resistance (3.1 Wood units [IQR, 2.0-5.7] vs. 6.9 Wood units [IQR, 4.0-12.9]; P<0.0001) and in improvements in median stroke volume/pulmonary pulse pressure ratio (2.6 ml/mm Hg [IQR, 1.8-3.5] vs. 1.4 ml/mm Hg [IQR 8.9-2.4]; P<0.0001) and mean (±SD) tricuspid annular plane systolic excursion (2.2±0.12 cm vs. 1.65±0.11 cm; P<0.0001), 6-minute walk distance (395±99 m vs. 343±131 m; P = 0.001), and serum N-terminal pro-brain natriuretic peptide (647±1,127 pg/ml vs. 1,578±2,647 pg/ml; P<0.05). Conclusions: Up-front combination therapy with ambrisentan and tadalafil significantly improved hemodynamics, RV structure and function, and functional status in treatment-naive patients with SSc- PAH andmay represent a very effective therapy for this patient population. In addition, we identified novel hemodynamic and imaging biomarkers that could have potential value in future clinical trials.
AB - Background: Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is a rare disease characterized by a very dismal response to therapy and poor survival. We assessed the effects of up-front combination PAH therapy in patients with SSc-PAH. Methods: In this prospective, multicenter, open-label trial, 24 treatment-naive patients with SSc-PAH received ambrisentan 10 mg and tadalafil 40 mg daily for 36 weeks. Functional, hemodynamic, and imaging (cardiac magnetic resonance imaging and echocardiography) assessments at baseline and 36 weeks included changes in right ventricular (RV) mass and pulmonary vascular resistance as co-primary endpoints and stroke volume/pulmonary pulse pressure ratio, tricuspid annular plane systolic excursion, 6-minute walk distance, and N-terminal pro-brain natriuretic peptide as secondary endpoints. Results: At 36 weeks, we found that treatment had resulted in significant reductions in median (interquartile range [IQR])RVmass (28.0 g [IQR, 20.6-32.9] vs. 32.5 g [IQR, 23.2-41.4]; P<0.05) and median pulmonary vascular resistance (3.1 Wood units [IQR, 2.0-5.7] vs. 6.9 Wood units [IQR, 4.0-12.9]; P<0.0001) and in improvements in median stroke volume/pulmonary pulse pressure ratio (2.6 ml/mm Hg [IQR, 1.8-3.5] vs. 1.4 ml/mm Hg [IQR 8.9-2.4]; P<0.0001) and mean (±SD) tricuspid annular plane systolic excursion (2.2±0.12 cm vs. 1.65±0.11 cm; P<0.0001), 6-minute walk distance (395±99 m vs. 343±131 m; P = 0.001), and serum N-terminal pro-brain natriuretic peptide (647±1,127 pg/ml vs. 1,578±2,647 pg/ml; P<0.05). Conclusions: Up-front combination therapy with ambrisentan and tadalafil significantly improved hemodynamics, RV structure and function, and functional status in treatment-naive patients with SSc- PAH andmay represent a very effective therapy for this patient population. In addition, we identified novel hemodynamic and imaging biomarkers that could have potential value in future clinical trials.
KW - MRI
KW - Pulmonary arterial hypertension
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=84946565060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946565060&partnerID=8YFLogxK
U2 - 10.1164/rccm.201507-1398OC
DO - 10.1164/rccm.201507-1398OC
M3 - Article
C2 - 26360334
AN - SCOPUS:84946565060
SN - 1073-449X
VL - 192
SP - 1102
EP - 1110
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 9
ER -